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models. ConClusions: The specified mapping algorithms from the BDI index to 
the EQ-5D-3L index for patients with depressive disorders are acceptable for usage 
as approximation in cost-utility analyses. A further validation in independent sam-
ples is necessary to obtain more confidence in their performance.
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objeCtives: LPLD is an ultra-orphan genetic lipid disorder (prevalence 1-2/mil-
lion). It is associated with severe hypertriglyceridemia and an increased risk of 
acute pancreatitis. Other manifestations include eruptive xanthoma, fatigue, dif-
ficulty with concentrating and cardiopulmonary symptoms. Associated symptoms, 
complications and the fat-restricted diet affect Quality of Life (QOL). Currently no 
disease-specific measure exists to assess QOL and the burden of LPLD. As part of 
post approval commitments of alipogene tiparvovec, regulatory bodies requested 
the development of a reliable measure of QOL in LPLD. This study evaluates exist-
ing EORTC questionnaires QLQ-C30 and QLQ-PAN26, and a new questionnaire of 
disease burden devised by clinicians with experience in treating LPLD. Methods: 
To date, eight genetically confirmed LPLD-patients from four countries assessed 
the relevance and importance of each item of the three questionnaires. Patients’ 
ratings were discussed during an in-depth, face-to-face interview and the dis-
ease burden questionnaire was comprehensively discussed, analyzed and then 
modified where necessary. Results: Quantitative assessment showed that 25 
(45%) of the QLQ-C30 and QLQ-PAN26 questions were relevant to the majority of 
patients. The most relevant items were pain (6), fatigue and sleeping problems 
(4), digestive and dietary factors (4), work, daily and social activity restrictions (4) 
and impact on emotional functioning (3). Qualitative and quantitative analysis 
of the new questionnaire highlighted the unpredictability of pancreatitis attacks 
and the impact of the strict low fat diet on social and emotional factors. Less 
common clinical manifestations of LPLD (xanthoma, dyspnea) were very impor-
tant to those affected. The new questionnaire has been modified and items on 
alcohol use and painkillers added for ongoing evaluation. ConClusions: Five 
QOL domains relevant to LPLD have been identified using existing questionnaires. 
A new disease-specific questionnaire identifies significant impacts on patients’ 
lives. These instruments may help clinicians to effectively use pharmacological 
and genetic therapy to manage LPLD patients.
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objeCtives: The Minnesota Living with Heart Failure Questionnaire (MLHFQ) is 
one of the most widely used health-related quality of life (HRQoL) specific ques-
tionnaires for patients with heart failure (HF). It provides two dimensions (physical 
and emotional) and a global score. However, there are some concerns about its 
factor structure, and different alternatives have been proposed, including even a 
third factor representing a social dimension. The objective of the present study 
was to study the internal structure of the MLHFQ, the unidimensionality of the 
total score, and to compare the different factor structures raised. Methods: We 
included 2565 patients hospitalized for HF, who were provided with the MLHFQ 
during hospitalization. The structural validity of the questionnaire was studied 
by confirmatory factor analysis (CFA) for categorical data, and the Rasch rating 
scale model. These two approaches were also applied to the different structures 
proposed. Results: The results of the CFA for the hypothesized model of two 
latent factors and the Rasch analysis confirmed the adequacy of the physical and 
emotional dimensions. We only found two problematic items within the total 
score. The results of the CFA applied to other two-factor structures proposed were 
not better than the results of the original structure. The Rasch analysis applied 
to the different social factors showed the best results for Munyombwe’s social 
dimension. ConClusions: The results support the validity of using the MLHFQ 
physical and emotional subscales in patients with HF, as well as the total score. 
In addition, the results confirmed the existence of a third social factor, and we 
recommend the use of Munyombwe’s social factor.
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last-visit versions, whilst other items should be scored individually. The last-visit 
version discriminates treatment response.
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objeCtives: In recent years, the healthcare industry has witnessed a trend for regula-
tory approvals of innovative technologies in oncology without head-to-head clinical 
trial evidence or Health Related Quality-of-Life (HRQoL) data. This yields a challenge 
to decision-makers who require a cost-effectiveness analysis (CEA) to conduct Health 
Technology Assessments. To demonstrate methodological approaches and potential 
data sources to address these gaps, we present a case study using recently approved 
drugs lenvatinib and sorafenib for management of radioiodine-refractory differenti-
ated thyroid cancer (RR-DTC). Methods: A vignette study was conducted to elicit 
utilities for RR-DTC health-states and estimate the impact of toxicities on HRQoL. 
Phase III clinical trial data with crossover correction were used to compare clinical-
endpoints of Progression Free Survival (PFS) and Overall Survival (OS) for both len-
vatinib and sorafenib. Adjustments for study population differences were addressed 
using Matching-Adjusted Indirect Comparison. PFS and OS data were extrapolated 
to 10 years using proportional hazard, accelerated time failure, individual parametric 
models and piecewise models and time in health states was estimated from the 
partitioning of survival time into pre- and post-progression. Results: Adjusted 
HRs for lenvatinib vs. sorafenib were estimated as 0.37(95%CI: 0.25-0.55) for PFS and 
0.79(0.45-1.37) for OS. PFS (stable) health-state utilities for each drug were adjusted 
using tumor response rates and incremental utility gain. Combining phase III toxicity 
rates with utility decrements yielded a total disutility of 0.042 for lenvatinib vs. 0.117 
for sorafenib. Survival extrapolation (undiscounted) provided estimates of incremen-
tal 0.66 LYS and 0.60 QALY for lenvatinib vs. sorafenib. ConClusions: This analysis 
demonstrated that in absence of head-to-head trials and QoL trial data, vignette utility 
studies and ITC may be used to aid with QALY analysis, especially in orphan diseases 
where limited data are available. Vignette studies and ITC can increase reliability of 
comparative-effectiveness data and support payers’ decision making.
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objeCtives: Lack of rigour in PRO data analysis leads to uncertainty around the 
quality of results impacting the extent to which conclusions can be drawn from 
the data. This study sought to provide guidelines for PRO efficacy data analysis for 
study sponsors in order to ensure confidence in PRO results by stakeholder decision 
makers. Methods: A targeted review was undertaken of guidelines for clinical 
trial and PRO data analysis, and published PRO analysis studies that demonstrated 
good practice in PRO efficacy analysis. The evidence was synthesised by a team 
comprising statistical and PRO experts experienced in the analysis of PRO efficacy 
data. An 8-step guideline was developed based on the available evidence. Results: 
Eight steps that will ensure high quality analysis of PRO trial efficacy data are (1) 
avoid unplanned or post analysis by developing a PRO specific SAP prior to data 
base lock, or document comprehensive PRO data analysis in the clinical trial SAP 
(2) ensure awareness of differing requirements across stakeholders in PRO data 
analysis/interpretation and adequately address this in the SAP to ensure (3) specify 
primary and secondary PRO endpoints and/or approaches to correcting for multi-
plicity (4) develop and specify appropriate approaches to handling missing data 
including sensitivity analysis (5) include analysis of PRO score change from base-
line (6) specify approaches to interpreting change from baseline data including 
any benchmarks which will be applied during interpretation (7) implement a 100% 
double programming approach alongside table review by statistically qualified team 
members (8) interpret PRO results not only in isolation but alongside other clini-
cal outcomes ConClusions: For PRO data to effectively inform decision making 
across all stakeholders, high standards of data analysis needs to be mandatory. This 
8-step guideline, if adhered to, will raise the standard of PRO data analysis reducing 
the likelihood that PRO data is discounted by decision makers.
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objeCtives: For cost-utility analyses, data on health state utilities, as provided by 
the EQ-5D-3L, is needed but not always available. This study specifies a mapping 
algorithm from the Beck Depression Inventory (BDI) index to the EQ-5D-3L index 
adjusted for specific socio-demographic variables for patients with depressive dis-
orders. Methods: A sample of 1,074 consecutive patients with depressive disorders 
from a psychotherapeutic outpatient clinic was included in the study. Standardized 
clinical interviews were applied to establish reliable diagnoses. For the prediction 
of the EQ-5D-3L index from the BDI index and selected patient socio-demographic 
characteristics, ordinary least squares regression with robust standard errors was 
used. Model prediction properties were tested using the root mean squared error 
and repeated random sub-sampling cross-validation. Results: The BDI index 
predicted the EQ-5D-3L index with a significant proportion of variance explained. 
The highest model goodness of fit was estimated for models with the BDI index 
and age as independent variables. The root mean squared error of the predicted 
EQ-5D-3L index in the validation samples ranged from 0.225 to 0.228 between the 
